Press Release Archive

03.26.2014

Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age

03.25.2014

Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts

03.25.2014

Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

03.22.2014

Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis

03.20.2014

Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease

03.18.2014

Pfizer Launches 2013 Integrated Annual Review

03.14.2014

U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery

03.12.2014

Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent

03.12.2014

Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014

03.12.2014

Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*

03.06.2014

Pfizer Initiates Nationwide Voluntary Recall Of Two Lots Of Pfizer's Effexor XR® 150 mg Extended-Release Capsules And One Lot Of Greenstone's Venlafaxine HCI 150 mg Extended-Release Capsules Due To The Possible Presence Of Tikosyn® Capsule

02.26.2014

Saniona Announces Collaboration With Pfizer To Research And Develop Small Molecule Treatments For Neurological Disorders.